Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

about

Effects of Long-Term Multimodal Psychosocial Treatment on Antipsychotic-Induced Metabolic Changes in Patients With First Episode Psychosis

P2860

Q58554430-D76A710E-9845-415B-B1DB-4874FA8D635F

P2860

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

Item

http://www.wikidata.org/entity/Q55513508

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@en

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@nl

type

Item

label

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@en

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@nl

prefLabel

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@en

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@nl

P1476

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

@en

P2093

Haley Abing

http://www.w3.org/2001/XMLSchema#string

Jacob Spertus

http://www.w3.org/2001/XMLSchema#string

Marcela Horvitz-Lennon

http://www.w3.org/2001/XMLSchema#string

Sharon-Lise Normand

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data.

Network meta-analysis of individual and aggregate level data.

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

Size of burden of schizophrenia and psychotic disorders.

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Impact of FDA black box advisory on antipsychotic medication use

Chlorpromazine equivalent doses for the newer atypical antipsychotics.

P2888

s41537-018-0053-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41537-018-0053-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105054506

http://www.w3.org/2001/XMLSchema#string

P698

29950586

http://www.w3.org/2001/XMLSchema#string

P921

weight gain

P932

6021430

http://www.w3.org/2001/XMLSchema#string

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

about

P2860

P2860

Risk of weight gain for specific antipsychotic drugs: a meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P932